- Organizations: Nicox
Pipeline
Nicox reports positive pre-NDA FDA meeting for IOP-lowering drop
NO-donating bimatoprost formulation remains on track for a summer 2026 new drug application submission.
Pipeline
Nicox reports positive phase 3 data on NCX 470 glaucoma eye drop
Topline results from the Denali trial support a future NDA submission for the nitric oxide-donating bimatoprost formulation to lower IOP.Pipeline
Nicox releases favorable phase 3b data on IOP-lowering glaucoma therapeutic
Exploratory Whistler trial reports statistically significant IOP lowering and uveoscleral outflow for NCX 470, an NO-donating bimatoprost formulation.Pipeline
Nicox reports analysis of phase 3 data on IOP-lowering glaucoma therapy
Mont Blanc trial is evaluating NCX 470, a formulation of nitric oxide and bimatoprost with a dual mechanism targeting OAG and OHT.
Business
Nicox and Glaukos sign global licensing option for glaucoma and retinal candidate
Agreement includes preclinical research for NCX 1728, the lead compound of a new class of nitric-oxide-donating molecule class.
Pipeline
Nicox reports favorable IOP lowering for OAG in phase 3 eye drop trial
Latest data from Mont Blanc study finds the NO-bimatoprost combo formulation surpasses latanoprost at all time points.
Business
Nicox selects biotech exec for CEO as clinical focus shifts
Effective Feb. 29, Gavin Spencer, PhD, has taken the helm while the company announces corporate debt restructuring.
Pipeline